Top

Published in:

Open Access 01-12-2020 | Rituximab | Correction

Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product

Authors: Dietger Niederwieser, Caroline Hamm, Patrick Cobb, Mindy Mo, Cecily Forsyth, Alessandra Tucci, Vladimir Hanes, Vincent Delwail, Roman Hajek, David Chien

Published in: Targeted Oncology | Issue 6/2020

Excerpt

Page 608, 4 Discussion, right column, second paragraph: The sentence, which previously read: …

Title: Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product
Authors: Dietger Niederwieser
Caroline Hamm
Patrick Cobb
Mindy Mo
Cecily Forsyth
Alessandra Tucci
Vladimir Hanes
Vincent Delwail
Roman Hajek
David Chien
Publication date: 01-12-2020
Publisher: Springer International Publishing
Keywords: Rituximab
Rituximab
Published in: Targeted Oncology / Issue 6/2020
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-020-00772-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2020

Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping

Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry

Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study

Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3

Keynote webinar | Spotlight on antibody–drug conjugates in cancer